Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (121-130 of 250) with videos related to

Pageof 25
Sort By:
Haematologica|July 11, 2015
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara studyEnrique M Ocio, Pilar Herrera, María-Teresa Olave, et al.
The New England Journal of Medicine|August 2, 2013
Lenalidomide plus dexamethasone for high-risk smoldering multiple myelomaMaría-Victoria Mateos, Miguel-Teodoro Hernández, Pilar Giraldo, et al.
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Cancer|July 9, 2025
Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 studyCarolina Schinke, Cyrille Touzeau, Albert Oriol, et al.
British Journal of Haematology|June 6, 2020
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM groupEnrique M Ocio, Cristina Motlló, Paula Rodríguez-Otero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2006
Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 TrialJose-Maria Ribera, Juan-José Ortega, Albert Oriol, et al.
Haematologica|February 15, 2024
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA studyVerónica González-Calle, Paula Rodríguez-Otero, Anna Sureda, et al.
Leukemia Research Reports|October 27, 2015
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinationsAurelio Lopez, Maria-Victoria Mateos, Albert Oriol, et al.
Haematologica|April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaKatja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.
Cancers|December 8, 2020
Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical TrialNoemí Puig, Luis A Corchete-Sánchez, José J Pérez-Morán, et al.
Pageof 25

Showing results (121-130 of 250) with videos related to

Sort By:
Pageof 25
Haematologica|July 11, 2015
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara studyEnrique M Ocio, Pilar Herrera, María-Teresa Olave, et al.
The New England Journal of Medicine|August 2, 2013
Lenalidomide plus dexamethasone for high-risk smoldering multiple myelomaMaría-Victoria Mateos, Miguel-Teodoro Hernández, Pilar Giraldo, et al.
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Cancer|July 9, 2025
Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 studyCarolina Schinke, Cyrille Touzeau, Albert Oriol, et al.
British Journal of Haematology|June 6, 2020
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM groupEnrique M Ocio, Cristina Motlló, Paula Rodríguez-Otero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2006
Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 TrialJose-Maria Ribera, Juan-José Ortega, Albert Oriol, et al.
Haematologica|February 15, 2024
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA studyVerónica González-Calle, Paula Rodríguez-Otero, Anna Sureda, et al.
Leukemia Research Reports|October 27, 2015
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinationsAurelio Lopez, Maria-Victoria Mateos, Albert Oriol, et al.
Haematologica|April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaKatja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.
Cancers|December 8, 2020
Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical TrialNoemí Puig, Luis A Corchete-Sánchez, José J Pérez-Morán, et al.
Pageof 25